Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition
Share
The logo of Danish pharmaceutical company Novo Nordisk at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty ImagesNovo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc.Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases.
Related Articles
China NewsChinese RegimeEducationInternational RelationsNational SecurityOhio NewsRegional & State NewsState NewsThreat from Communist ChinaUSUS NewsUS-China Relations
Ohio State Agrees to $2.1 Million Federal Settlement Over Undisclosed China Research Ties
Ohio State University has agreed to pay $2.1 million to resolve federal...
BusinessEconomyUSUS News
USDA Unveils New Support for Ranchers to Rebuild Cattle Herds
The U.S. Department of Agriculture has unveiled a new package of measures...
BrightBusinessInvestingMarketsPersonal FinanceStocks
How Major US Stock Indexes Fared Aug. 31
Oil prices rose and U.S. stocks fell after American forces struck Iranian...
BusinessCompaniesExecutive BranchUSUS NewsUS Politics
Trump Unveils New Drug Pricing Deals With 9 Pharmaceutical Companies
President Donald Trump on Aug. 31 announced agreements with nine midsize pharmaceutical...
